Evidence map›Paper›PMID 36615409›Full record

ArticleMolecules (Basel, Switzerland)2022

Clove Essential Oil and Its Main Constituent, Eugenol, as Potential Natural Antifungals against

Anna Biernasiuk, Tomasz Baj, Anna Malm

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Surface Carrier Testing of Hospital Antiseptics AgainstPathogens (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Multifunctional Activity ofInternational journal of molecular sciences · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Insights fromPharmaceuticals (Basel, Switzerland) · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Anna BiernasiukDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0002-2844-9876
Tomasz BajDepartment of Pharmacognosy with the Medicinal Plants Garden, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0001-7543-6771
Anna MalmDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Medical University of Lublin, 20-093 Lublin, Poland.ORCID 0000-0003-1503-7634
Medical University of Lublin · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The occurrence of candidiasis, including superficial infections, has recently increased dramatically, especially in immunocompromised patients. Their treatment is often ineffective due to the resistance of yeasts to antimycotics. Therefore, there is a need to search for new antifungals. The aim of this study was to determine the antifungal effect of clove essential oil (CEO) and eugenol (EUG) towards both reference and clinical

Indexed as

CandidiasisOils, VolatileSyzygiumAntifungal AgentsCandidaClove OilErgosterolEugenolHumansMicrobial Sensitivity TestsAntifungal AgentsClove OilErgosterolEugenolOils, Volatileantifungal activityCandida spp.clove essential oileugenolinteractionsmode of actions

Identifiers

PMID36615409
PMCPMC9821947
OpenAlexW4313244259

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.